
At Interfector Therapeutics, our mission is to pioneer transformative therapies that address unmet needs in oncology and enhance patients’ quality of life.
We are committed to advancing scientific frontiers through the discovery and development of novel, first-in-class investigational agents targeting critical pathways in cancer biology.

With over five decades of combined expertise in medicine and drug discovery, our team is driven by innovation, precision, and patient-centered purpose. We aim to transform promising molecular discoveries into groundbreaking therapeutics that improve survival and extend healthy lifespan.

Our multidisciplinary team unites leaders in oncology, translational research, pharmaceutical development, and biotechnology entrepreneurship. Together, we are committed to accelerating the transition from discovery to clinic, with a shared vision of delivering curative outcomes for patients worldwide.
Please reach us at info@interfectortherapeutics.com if you cannot find an answer to your question.
Founded in 2024, Interfector Therapeutics emerged from a strategic collaboration between Dr. Daruka Mahadevan and Dr. Eloïse Dray, along with their expert network of scientific and clinical collaborators. Fueled by a common mission to address urgent unmet needs in advanced cancers, Interfector Therapeutics unifies a robust drug development pipeline and multidisciplinary expertise to deliver hope through innovation.
We are developing anti-cancer drugs to address unmet needs. Our research and development programs focus on:
We love to interact, so please email to schedule a visit during normal business hours.
Open today | 09:00 am – 05:00 pm |
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.